Early palliative care of non‑small cell lung cancer in the context of immunotherapy (Review)
- Małgorzata Pieniążek
- Piotr Pawlak
- Barbara Radecka
Affiliations: Department of Oncology, Institute of Medical Sciences, University of Opole, 45‑040 Opole, Poland, Department of Clinical Oncology, Tadeusz Koszarowski Cancer Center, 45‑061 Opole, Poland
- Published online on: October 29, 2020 https://doi.org/10.3892/ol.2020.12259
Copyright: © Pieniążek
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The most common cause of mortality due to malignant neoplasms in the general population around the world is lung cancer. In the last 10 years, there has been an enormous improvement in the treatment of this disease, mainly due to the immunotherapy that activates the immune system to fight cancer. Patients with metastatic non‑small cell lung cancer are a special group of patients requiring not only cancer treatment but also considerable support in the treatment of cancer‑related problems, as well as comorbidities. Early palliative care is important in this area. In addition, there is certain evidence that medicines most commonly administered in palliative care may lower the efficacy of immunotherapy. The present review article compares information on the prolonging of life after early hospice care, which has become the foundation of current standards of management in patients with metastatic lung cancer, and reports of decreased efficacy of the immunotherapy due to the administration of major palliative care medications.